Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis
Several clinical trials that tested the efficacy of systemic treatments for advanced hepatocellular carcinoma (HCC) showed a tendency that patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection had different survival benefits from targeted agents.
The objective of this study was to assess the comparative efficacy of systemic targeted therapies according to HBV and HCV status in first-line and second- or later-line treatments for advanced HCC.
PubMed, EMBASE, Cochrane database, and meeting abstracts were searched through to January 2019. A Bayesian network meta-analysis was performed to estimate hazard ratios (HRs) for overall survival with 95% credible intervals (CrIs) and determine the ranking of the included regimens.
Sixteen trials involving 6410 patients were included in the meta-analysis. In the first-line treatment setting, lenvatinib was the best agent for both HBV and HCV subgroups, presenting the most favorable HR versus sorafenib (HR 0.83, 95% CrI 0.68–1.01 and HR 0.91, 95% CrI 0.66–1.25, respectively), and was ranked as the best agent [surface under the cumulative ranking curve (SUCRA) value of 87% and 85%, respectively] among the included drugs. In second-line therapy, regorafenib showed the lowest HR versus placebo (HR 0.58, 95% CrI 0.41–0.82) in the HBV subgroup, whereas no agent was significantly more effective than placebo in the HCV subgroup.
Compared with sorafenib, lenvatinib was more efficacious in the HBV subgroup than in the HCV subgroup, and the relative ranking of sorafenib in the HBV subgroup was lower than in the HCV subgroup. Each targeted agent reported to be the best by viral etiology and line of treatment could be carefully recommended in each subgroup.
Compliance with Ethical Standards
No external funding was used in the preparation of this manuscript.
Conflict of interest
Jisun Park, Jinhyun Cho, Joo Han Lim, Moon Hee Lee, and Jinchul Kim declare that they have no conflicts of interest that might be relevant to the content of this article.
- 3.El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(1264–73):e1.Google Scholar
- 8.National Comprensive Cancer Network. NCCN clinical practice guidelines in oncology: hepatobiliary cancers, version 5. 2018. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed Dec 2018.
- 25.Tak WY, Ryoo BY, Lim HY, Kim DY, Okusaka T, Ikeda M, et al. Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. Invest New Drugs. 2018;36:1072–84.CrossRefGoogle Scholar
- 26.Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–70.CrossRefGoogle Scholar
- 29.Peixoto RD, Renouf DJ, Gill S, Cheung WY, Lim HJ. Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. J Gastrointest Oncol. 2014;5:259–64.Google Scholar
- 36.Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008;48:83–90.CrossRefGoogle Scholar